<DOC>
	<DOCNO>NCT00975312</DOCNO>
	<brief_summary>Background - Lentigines usually first sign photoaging may produce significant impact patient ' quality life . - There treatment choice condition . - Solar lentigo melasma share similar physiopathologic characteristic . - The triple combination ( TC ) cream ( hydroquinone 4 % , tretinoin 0.05 % , fluocinolone acetonide 0.01 % ) effective safe treatment melasma hyperpigmented lesion . Hypothesis * The TC cream effective safe treatment solar lentigo back hand . Patients method - 22 patient solar lentigo select right hand leave hand select random treat either TC cream tretinoin 0.05 % cream daily 12 week . - Patients instructed apply cream whole back hand lentigo , use broad-spectrum sunscreen ( SPF 50+ , UVA-PF 28 ) daily hand . - Clinical assessment Target Lesion Pigmentation , Physician 's Global Assessment Improvement Subject 's Self-Assessment questionnaire collect data analysis week 4 , 8 , 12 start treatment 3 month post-treatment . - Statistical method : The ordinally scaled efficacy measure underwent rank transformation analyze analysis variance test null hypothesis difference among treatment . We perform Mann-Whitney Wilcoxon test XLSTAT 2009 software use .</brief_summary>
	<brief_title>Solar Lentigines Treatment With Triple Combination Cream</brief_title>
	<detailed_description />
	<mesh_term>Lentigo</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<mesh_term>Hydroquinone</mesh_term>
	<criteria>Subjects sex 30 80 year age . Phototype IIV . Postmenopausal woman childbearing age user contraception method negative pregnancy test ( beta subunit chorionic gonadotropin blood ) baseline maintain contraceptive treatment investigation . Subjects 10 solar lentigo back hand wich treat last 6 month Patients 30 80 year age . Skin type I VI . Less 10 solar lentigo back hand . Patients receive receive treatment lentigo back hand . Women childbearing age without contraceptive therapy . Pregnancy lactation . History hypersensitivity component drug . Simultaneous use topical skin lightening . Patient refusal participate study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>lentigo</keyword>
	<keyword>hydroquinone</keyword>
	<keyword>tretinoin</keyword>
	<keyword>fluocinolone acetonide</keyword>
</DOC>